智通财经APP讯，固生堂(02273)发布公告，于2025年12月9日该公司斥资959.73万港元回购34.01万股， 回购价格为每股28.02-28.40港元。 ...

Core Viewpoint - The launch of the National Medical Insurance Administration's drug price registration system reflects a strong support for pharmaceutical innovation and aims to enhance the modernization of drug price governance in China [1] Group 1: Drug Price Registration System - The new system operates on the principles of "one location for acceptance, nationwide sharing, and global openness," providing drug price registration and inquiry services for domestic and foreign pharmaceutical companies [1] - This initiative is expected to facilitate the international expansion of Chinese innovative drugs and attract high-quality new drugs from abroad into the Chinese market [1] Group 2: Market Dynamics - The importance of China's large-scale market in the global pharmaceutical landscape is increasing, leading to higher demands for improving the drug price governance system [1] - The pharmaceutical industry is experiencing a structural recovery trend, with both supply and demand sides reaching a turning point [1] Group 3: Investment Opportunities - The Guotai Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily fluctuation of up to 20% [1] - This index focuses on innovative pharmaceutical sectors, selecting listed companies with high R&D investment and strong innovation capabilities, reflecting the overall performance of leading companies in the pharmaceutical industry with growth and technological attributes [1]

社会保障信息服务中心分管医疗部门网络安全事务的工作人员李成勋（音译）介绍，如果提前备份 了各项数据，医院就可以在遭黑客攻击后尽快恢复系统数据，需要注意的是数据必须备份在外部硬盘 上，且与主系统处于物理隔离状态。然而，在现实操作中，许多医院没有遵循该原则。 12月4日，在韩国首尔，人们在雪中候车。新华社发（朴晋泽摄） 一些小诊所表示，自己完全无力应对这类威胁。一家诊所甚至表示，给计算机设置密码就是"唯一 能用的安全手段"。 《中央日报》说，在韩国，国立大学的附属医院可从教育部获取网络安全支持，但大部分医院需要 自行购买网络安全支持服务。若是购买社会保障信息服务中心的网络安全服务，每年需支付1200万韩元 （约合5.8万元人民币）至1800万韩元（约合8.7万元人民币）。出于成本考虑等诸多因素，许多医院并 未购买这项服务。在接受调查的270家大型综合医院中，只有20家购买了该服务；在接受调查的7万多家 小型诊所中，只有5家购买了该服务。 新华社北京12月9日电 韩国多家医院近来遭到黑客攻击，有些医院计算机系统被植入勒索软件，还 有的被威胁要曝光患者资料等敏感信息。仅有少数几家大医院迅速作出有效应对，大部分医院以及 ...

Group 1 - The medical services sector increased by 0.09% on December 9, with Zhaoyan New Drug leading the gains [1] - The Shanghai Composite Index closed at 3909.52, down 0.37%, while the Shenzhen Component Index closed at 13277.36, down 0.39% [1] - A table detailing the individual stock performance within the medical services sector was provided [1] Group 2 - The net inflow of main funds into the medical services sector was 514 million yuan, while retail funds experienced a net outflow of 384 million yuan [2] - The net outflow of speculative funds was 129 million yuan [2] - A table showing the fund flow for individual stocks in the medical services sector was included [2]

证券日报网讯12月9日晚间，博济医药（300404）发布公告称，公司获得国家知识产权局颁发的发明专 利证书，发明名称为"一种双氯芬酸钠药物制剂及其制备方法和应用"，专利号ZL202510581633.4，授权 公告日2025年12月5日。公司表示，该专利有利于技术创新，完善知识产权保护体系，提升核心竞争 力。 ...

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) has increased significantly, driven by a surge in the price of experimental monkeys, particularly the crab-eating macaque, which has seen a supply shortage and price increase [5]. Group 1: Company Performance - Zhaoyan New Drug's stock price rose by 7.33% to HKD 17.43, with a trading volume of HKD 211 million [5]. - The company is expected to benefit from the rising prices of experimental monkeys due to its acquisition of monkey breeding facilities, which aims to create an integrated industry chain [5]. Group 2: Industry Trends - The price of crab-eating macaques has surpassed HKD 100,000, with reports indicating prices have reached HKD 120,000 to HKD 130,000 due to supply shortages [5]. - Demand for experimental monkeys is projected to be between 51,300 to 62,600 annually from 2025 to 2027, while supply is estimated at 49,000 to 52,400, indicating a potential supply-demand gap [5]. - The resurgence in new drug development is expected to drive up the usage of experimental monkeys, exacerbating the supply constraints in the short term [5].

Group 1 - The core viewpoint of the article highlights a significant increase in the price of experimental monkeys, particularly the crab-eating macaques, which have surpassed 100,000 yuan, with reports indicating prices have risen to 120,000-130,000 yuan due to supply shortages [1] - The trading performance of Zhaoyan New Drug (603127) shows a rise of over 10%, currently at 17.8 HKD with a trading volume of 172 million HKD, indicating positive market sentiment [1] - According to estimates from Founder Securities, the supply of experimental monkeys is projected to be around 49,000-52,400 annually from 2025 to 2027, while demand is expected to be between 51,300-62,600, suggesting a widening supply-demand gap due to increased usage in new drug development [1] Group 2 - The report from招商证券 indicates that Zhaoyan New Drug's acquisition of monkey breeding facilities aims to create an integrated industry chain, positioning the company to benefit from the rising prices of experimental monkeys, which could enhance profit margins [1] - The short-term outlook suggests that the demand for experimental monkeys is driven by a resurgence in new drug research, while improvements in supply are expected to be challenging, potentially leading to a sustained supply-demand imbalance [1]

Core Viewpoint - The stock price of Zhaoyan New Drug (06127) has increased by over 10%, currently trading at 17.8 HKD with a transaction volume of 172 million HKD, driven by a significant rise in the price and demand for experimental monkeys [1] Group 1: Company Insights - Zhaoyan New Drug is expected to benefit from the rising prices of experimental monkeys, as the company has acquired monkey farms to create an integrated industry chain [1] - The company’s stock performance reflects market optimism regarding its future profitability linked to the rising costs of experimental monkeys [1] Group 2: Industry Trends - The price of the crab-eating macaque has surpassed 100,000 RMB, with reports indicating that prices have reached 120,000 to 130,000 RMB due to a supply shortage [1] - Demand for experimental monkeys is projected to be between 51,300 to 62,600 units annually from 2025 to 2027, while supply is estimated at 49,000 to 52,400 units per year, indicating a potential supply-demand gap [1] - The short-term increase in demand for experimental monkeys is driven by a resurgence in new drug development, while supply-side improvements are expected to be challenging [1]

Core Viewpoint - The Weifang Municipal Commission for Discipline Inspection and Supervision is actively addressing issues related to redundant medical examinations and improper charges in the healthcare sector, aiming to alleviate the financial burden on citizens [1][2][3] Group 1: Issues Addressed - The Weifang Municipal Commission has focused on resolving public concerns regarding excessive medical examinations and high treatment costs by implementing a rectification plan in collaboration with health authorities [1] - A comprehensive review of complaints related to redundant medical checks and improper charges has been conducted, resulting in the establishment of a rectification ledger for 78 identified issues [1][3] Group 2: Supervision and Monitoring - The Commission employs various methods, including participation in health committee meetings and on-site inspections, to continuously monitor and address the challenges of redundant medical examinations and improper charges [2] - A new monitoring platform, "E-Lian Tong," has been developed to oversee key areas such as drug procurement and material management, enhancing the ability to detect and warn against irregularities [2] Group 3: Outcomes and Measures - Since the initiation of the rectification efforts, the Commission has identified 31 specific issues related to non-compliant medical practices, leading to the investigation and disciplinary action against five individuals [3] - The healthcare system in Weifang has improved collaboration among various departments, enhancing data analysis and joint assessments to prevent unnecessary redundant medical examinations [3]

2025年12月6日，一场汇聚中外医学智慧、跨越学科边界的学术盛会——"人体复杂系统运行规律及疑难 疾病临床决策研讨会"通过线上方式隆重举行。本次会议由中国生物多样性与绿色发展基金会肿瘤生态 委员会、中国老年保健协会肿瘤支持专业委员会牵头，联合中国慈善总会科技与文化发展委员会、中国 科学院数学与系统科学研究院、北京中西医慢病防治学会、经方与现代中药融合创新全国重点实验室、 肿瘤智库主动健康与疑难杂症临床决策中心、轻又清微生态健康食品研发中心、青岛普罗吉有限公司等 多家权威机构共同主办。会议上，基于创新理论构建的"肿瘤智库复杂疾病决策平台"——肿瘤生态学一 站式诊疗平台上线，标志着针对癌症中晚期、慢性病等复杂疾病的诊疗，开始从传统的"分科对抗"模 式，转向"系统调控、生态重建"的新范式。 会议提出的"人体复杂系统运行规律与疑难复杂疾病临床决策理论体系"认为，人体应被理解为一个具备 多层反馈、高度整合的智能生态系统，通过精密调节维持动态平衡。而疾病，尤其是疑难复杂疾病，是 跨尺度（从基因到环境）、动态演进中的"系统失稳"过程，远非单一器官的故障。 会议认为，必须打破传统以症状和器官为中心的疾病分类束缚，构建融合遗 ...